参芍口服液对糖尿病肾病大鼠肾脏NLRP3炎症复合体相关蛋白表达的影响被引量：14

下载PDF

导出

摘要目的探讨参芍口服液对糖尿病肾病(DN)模型大鼠肾脏核苷酸结合寡聚化结构域样受体3炎症性复合体(以下简称NLRP3炎症体)表达的影响及对肾脏的保护作用。方法选择健康雄性Wistar大鼠45只,随机分为模型组、治疗组、对照组各15只。模型组、治疗组予一次性腹腔注射STZ制备DN模型,对照组腹腔注射等剂量的生理盐水。造模成功后,治疗组给予参芍口服液250 mg/(kg·d)灌胃,对照组和模型组给予等量生理盐水灌胃,均干预12周。各组大鼠干预12周后,以代谢笼收集24 h尿液,检测24 h尿量及尿蛋白定量(PRO),断尾取血测定血糖、血清Scr、血BUN。采用Masson染色法观察肾脏组织病理改变。采用免疫组化法检测肾脏组织NLRP3炎症体成分核苷酸结合寡聚化结构域样受体3(NLRP3)、半胱氨酸天冬氨酸蛋白酶1(Caspase-1)、IL-1β蛋白定性表达,采用Western blot法检测肾脏组织NLRP3、Caspase-1、IL-1β蛋白表达量。结果治疗组、对照组血糖、24 h尿量、PRO、血Scr、血BUN均低于模型组(P均<0.05)。模型组肾小球中重度纤维化,系膜基质重度增生,基底膜明显增厚;治疗组病理改变较模型组明显减轻。模型组肾脏组织中NLRP3、Caspase-1及IL-1β的定性及定量表达均高于对照组及治疗组(P均<0.05)。结论参芍口服液可降低DN大鼠血糖水平、减轻肾脏纤维化、保护肾功能,其机制可能与降低肾脏组织中NLRP3炎症体相关蛋白NLRP3、Caspase-1、IL-1β的表达有关。

作者李海鸥张红利贾春新周洪霞张春来

机构地区唐山工人医院华北理工大学

出处《山东医药》 CAS 北大核心 2016年第30期34-37,I0002,共5页 Shandong Medical Journal

关键词参芍口服液糖尿病肾病核苷酸结合寡聚化结构域样受体3 半胱氨酸天冬氨酸蛋白酶1 白细胞介素-1Β

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献18

1Gluhovschi G, Gluhovschi C, Bob F, et al. Trandafirescu immune compartments of the nephron in relation to the immune system[ J]. Romanian J Inter Med, 2010,48( 1 ) :17-31.
2Rodriguez IB, Johson R J, Hen'era AJ. Tubulointerstitial damage and progression of renal failure [ J ]. Kidn Intern Supp, 2005, (99) :82-86.
3Martinon F, Bums K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and process- ing ofpro IL-113[ J]- nol Cell, 2002,10(2) :417-426.
4Bauemfeind F, Ablasser A, Bartok E, et al. Inflammasomes : cur- rent understanding and open questions [ J ]. Cell Mol Life Sci, 2011,68 (5) :765-783.
5Tran TH, Pham JT, Shafeeq H, et al. Role of interleukin-1 inhibi- torsin the management of gout [ J ]. Pharmacotherapy, 2013,33 ( 7 ) : 744 -753.
6Zhou R, Tardivel A, Thorens B, et al. Thioredoxin-interaeting protein links oxidative stress to inflammasome activation [ J ]. Nat Immunol, 2010,11 (2) : 136-140.
7Halle A, Homung V, Petzold GC, et al. The NALP3 inflamma- some is involved in the innate immune response to amyloid-β[ J ]. Nat Immunol, 2008,9(8) :857-865.
8Li X, Zhang Y, Xia M, et al. Activation of Nlrp3 inflammasomes enhances macrophage lipid-deposition and migration;implication of a novel role of inflammasome in atherogenesis [ J ]. PLoS One, 2014,9( 1 ) :87552.
9李霞,贺博然,纪征,尚小明,张春来.宽心合剂对大鼠心脏急性缺血-再灌注损伤后心肌纤维化的影响[J].中国中医基础医学杂志,2010,16(7):599-600. 被引量：2
10许毓申,王国宏,边延涛,秦明照,袁申元.糖尿病心肌病早期心肌局部血管紧张素Ⅱ和一氧化氮的变化[J].心肺血管病杂志,2001,20(4):241-243. 被引量：9

二级参考文献24

1何继强,王绿娅,刘晓惠.血管紧张素Ⅱ与动脉粥样硬化形成的研究进展[J].中国动脉硬化杂志,2004,12(3):360-362. 被引量：7
2施志明,钱晓明,许瑞吉,周晓军,陈云,章俐,吴振国.实验性糖尿病大鼠心肌ATⅡ和心肌超微结构的研究[J].中国糖尿病杂志,1996,4(1):28-30. 被引量：39
3Cleutiens JPM, Verluyten MJA, Smith JFM, et al. Collagen remodeling after myocardial infarction in the rat heart[ J]. Am J nathol. 1995.147:325-328.
4Shirakawa K, Miura T, Yamakawa K et al; Effect of ischemic preconditioning on the expression of TNF-a and the induction of apoptosis in the is chemia-reperfused rat heart [ J ]. Circulation, 1995,92(Suppl 1) :773.
5Capasso JM, Li P, Zhang X, et al. Heterogeneity of ventricular remolding after acute myocardial infarction in rats [ J ]. Am J Physiol, 1992,262 : H486-H495.
6Preffer MA. Left ventrlcular remodeling after myocardial infarction[J]. Ann Rev Med,1995,46(2):455-466.
7Endo J, Arita M. Roles of lipid mediators in controlling vascular inflammation and the progression of atherosclerosis [J]. Nihon Rinsho, 2011, 69(1): 34-38.
8Marx JL. Atherosclerosis : the cholesterol connection [ J ]. Science, 1976, 194 (4266) : 711-755.
9Javeshghani D, Barhoumi T, Idris-Khodja N, et al. Re- duced macrophage-dependent inflammation improves endo- thelin-l-induced vascular injury [ J ]. Hypertension, 2013, 62(1) : 112-117.
10Watanabe H, Ueda T, Miura M. Thromboxane A2 (TXA2), thromboxane B2 (TXB2) [ J ]. Nihon Rinsho, 2010, 68 Suppl 7 : 33-37.